S&P 500 rises to a record as Nvidia soars, investors look for rate cuts: Live updates

Shares of Madrigal Pharmaceuticals and others developing treatments for a serious liver condition tumbled on Wednesday after Eli Lilly shared preliminary abstract data illustrating how effective tirzepatide can be for this group. Madrigal shares fell more than 7% on Wednesday.

However, Piper Sandler analyst Yasmeen Rahimi reiterated an overweight rating on the stock, emphasizing that Madrigal is the only company with Food and Drug Administration approval to treat the disorder, metabolic dysfunction-associated steatohepatitis, or MASH. The disease, which was previously called nonalcoholic steatohepatitis, or NASH, is characterized by a build-up of fatty deposits in the liver. Shares of rival 89bio were recently down more than 2%, off its lows for the day.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stock Market Today: S&P 500 snaps win streak as rising yields steal Nvidia's shineStock Market Today: S&P 500 snaps win streak as rising yields steal Nvidia's shine
Source: Investingcom - 🏆 450. / 53 Read more »

CNBC Daily Open: S&P 500 and Nasdaq hit new heights ahead of Nvidia's earningsFederal Reserve Governor Christopher Waller said he does not think further rate increases are necessary, but he will need convincing before backing any rate cuts.
Source: CNBC - 🏆 12. / 72 Read more »

Stock Market Today: S&P 500, Nasdaq in record close ahead of Nvidia earningsStock Market Today: S&P 500, Nasdaq in record close ahead of Nvidia earnings
Source: Investingcom - 🏆 450. / 53 Read more »

Dow Jones, Nasdaq, S&P 500 weekly preview: It's the Nvidia earnings weekDow Jones, Nasdaq, S&P 500 weekly preview: It's the Nvidia earnings week
Source: Investingcom - 🏆 450. / 53 Read more »